1. Home
  2. DAWN vs MPB Comparison

DAWN vs MPB Comparison

Compare DAWN & MPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DAWN
  • MPB
  • Stock Information
  • Founded
  • DAWN 2018
  • MPB 1868
  • Country
  • DAWN United States
  • MPB United States
  • Employees
  • DAWN N/A
  • MPB N/A
  • Industry
  • DAWN Biotechnology: Pharmaceutical Preparations
  • MPB Major Banks
  • Sector
  • DAWN Health Care
  • MPB Finance
  • Exchange
  • DAWN Nasdaq
  • MPB Nasdaq
  • Market Cap
  • DAWN 624.8M
  • MPB 628.8M
  • IPO Year
  • DAWN 2021
  • MPB N/A
  • Fundamental
  • Price
  • DAWN $7.20
  • MPB $29.90
  • Analyst Decision
  • DAWN Strong Buy
  • MPB Buy
  • Analyst Count
  • DAWN 7
  • MPB 2
  • Target Price
  • DAWN $27.86
  • MPB $34.50
  • AVG Volume (30 Days)
  • DAWN 2.1M
  • MPB 102.3K
  • Earning Date
  • DAWN 08-05-2025
  • MPB 07-23-2025
  • Dividend Yield
  • DAWN N/A
  • MPB 2.81%
  • EPS Growth
  • DAWN N/A
  • MPB N/A
  • EPS
  • DAWN N/A
  • MPB 2.30
  • Revenue
  • DAWN $187,638,000.00
  • MPB $191,454,000.00
  • Revenue This Year
  • DAWN $16.42
  • MPB $24.31
  • Revenue Next Year
  • DAWN $47.52
  • MPB $13.74
  • P/E Ratio
  • DAWN N/A
  • MPB $12.36
  • Revenue Growth
  • DAWN 2190.50
  • MPB 13.34
  • 52 Week Low
  • DAWN $5.64
  • MPB $22.50
  • 52 Week High
  • DAWN $16.76
  • MPB $33.87
  • Technical
  • Relative Strength Index (RSI)
  • DAWN 62.39
  • MPB 67.47
  • Support Level
  • DAWN $6.71
  • MPB $28.02
  • Resistance Level
  • DAWN $7.12
  • MPB $28.64
  • Average True Range (ATR)
  • DAWN 0.32
  • MPB 0.52
  • MACD
  • DAWN 0.10
  • MPB 0.20
  • Stochastic Oscillator
  • DAWN 85.05
  • MPB 98.36

About DAWN Day One Biopharmaceuticals Inc.

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.

About MPB Mid Penn Bancorp

Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.

Share on Social Networks: